A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC
Por:
Krebs, MG, Helland, A, Costa, EC, Aperribay, EA, Gomez, MD, Perez, JT, Thompson, J, Strauss, J, Granados, ALO, Felip, E, Schmidt, E, Chisamore, M, Madeleine, N, Rayford, A, Lorens, K, Siddiqui, A, Gabra, H, Nautiyal, J, Micklem, D, Lorens, J and Spicer, J
Publicada:
1 mar 2021
Resumen:
Filiaciones:
Krebs, MG:
Univ Manchester, Div Canc Sci, Manchester, Lancs, England
Christie NHS Fdn Trust, Manchester, Lancs, England
Helland, A:
Univ Oslo, Clin Med, Oslo, Norway
Oslo Univ Hosp, Oslo, Norway
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
Aperribay, EA:
Hosp del Mar, Barcelona, Spain
Gomez, MD:
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
Perez, JT:
Hosp Univ Virgen de La Victoria, Malaga, Spain
Thompson, J:
Med Coll Wisconsin, Affiliated Hosp, Menomonee Falls, WI USA
Strauss, J:
Mary Crowley Canc Res, Dallas, TX USA
Granados, ALO:
Complejo Hosp Jaen, Jaen, Spain
Felip, E:
Vall DHebron Inst Oncol Vhio, Dept Oncol, Barcelona, Spain
Schmidt, E:
Merck & Co Inc, Kenilworth, NJ USA
Chisamore, M:
Merck & Co Inc, Kenilworth, NJ USA
Madeleine, N:
Bergenbio Asa, Bergen, Norway
Rayford, A:
Bergenbio, Bergen, Norway
Lorens, K:
Bergenbio Asa, Bergen, Norway
Siddiqui, A:
Bergenbio Asa, Oxford, England
Gabra, H:
Bergenbio, Oxford, England
Nautiyal, J:
Bergenbio Asa, Oxford, England
Micklem, D:
Bergenbio, Bergen, Norway
Lorens, J:
Bergenbio, Bergen, Norway
Spicer, J:
Guys & St Thomas NHS Fdn Trust, Guys Hosp, London, England
|